Ani Pharmaceuticals (ANIP) Tax Provisions (2012 - 2026)

Ani Pharmaceuticals (ANIP) has 15 years of Tax Provisions data on file, last reported at $10.7 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions rose 149.51% year-over-year to $10.7 million; the trailing twelve-month figure through Mar 2026 stood at $23.9 million (up 467.73% YoY), and the FY2025 full-year result was $17.5 million, up 573.01% from the prior year.
• Tax Provisions improved to $10.7 million in Q1 2026, from $4.0 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $10.7 million in Q1 2026 to a low of -$7.3 million in Q3 2024.
• A 5-year average of $672625.0 and a median of $246500.0 in 2023 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions sank 57900.0% in 2022 and jumped 914.29% in 2024, its largest moves.
• Tracing ANIP's Tax Provisions over 5 years: stood at -$1.5 million in 2022, then jumped by 86.06% to -$207000.0 in 2023, then sank by 1585.99% to -$3.5 million in 2024, then jumped by 213.3% to $4.0 million in 2025, then soared by 171.35% to $10.7 million in 2026.
• Business Quant data shows ANIP's Tax Provisions at $10.7 million in Q1 2026, $4.0 million in Q4 2025, and $7.2 million in Q3 2025.